A 65-year-old male presents to the clinic for a routine follow-up evaluation. He has a his… — USMLE Step 3

A $65$ -year-old male presents to the clinic for a routine follow-up evaluation. He has a history of heart failure with reduced ejection fraction (left ventricular ejection fraction of $35\%$ ). Two weeks ago, spironolactone was added to his medical regimen, which already included sacubitril-valsartan, carvedilol, and dapagliflozin. The patient states he feels well and reports no shortness of breath, orthopnea, or lower extremity edema. His vital signs are within normal limits.

Laboratory studies obtained today show:
Serum sodium: $138 \text{ mEq/L}$
Serum potassium: $5.3 \text{ mEq/L}$ (Baseline: $4.5 \text{ mEq/L}$ prior to spironolactone)
Blood urea nitrogen: $22 \text{ mg/dL}$
Serum creatinine: $1.4 \text{ mg/dL}$ (Baseline: $1.2 \text{ mg/dL}$ )

Which of the following is the most appropriate next step in the management of this patient?

Continue the current medication regimen without changesAnswer
B
Discontinue spironolactone immediately
C
Discontinue sacubitril-valsartan immediately
D
Admit the patient to the hospital for continuous telemetry monitoring
E
Order a renal Doppler ultrasound

Answer

Continue the current medication regimen without changes

The correct answer is to continue the current medication regimen without changes. This patient with heart failure with reduced ejection fraction (HFrEF) recently started spironolactone. Mineralocorticoid receptor antagonists (MRAs) like spironolactone, as well as angiotensin receptor-neprilysin inhibitors (ARNIs) like sacubitril-valsartan, reduce renal perfusion pressure and decrease potassium excretion. It is a widely accepted clinical standard that a rise in serum creatinine of up to

30\%

from baseline and a mild increase in serum potassium (up to

5.5 \text{ mEq/L}

) are anticipated and acceptable physiological responses to these agents. Because the patient's creatinine increased by less than

20\%

(from

1.2

1.4 \text{ mg/dL}

) and his potassium is

5.3 \text{ mEq/L}

without symptoms, the medications should be continued to maintain their significant mortality benefit.

Step-by-Step Solution

Evaluate the patient's clinical status and laboratory results.

The patient is asymptomatic. Potassium is mildly elevated at

5.3 \text{ mEq/L}

and creatinine has increased from

1.2 \text{ mg/dL}

1.4 \text{ mg/dL}

To determine if the abnormalities represent a life-threatening emergency or an expected pharmacologic effect.

Assess the expected physiological effects of guideline-directed medical therapy (GDMT) for heart failure.

Spironolactone and sacubitril-valsartan can both cause mild hyperkalemia and a modest rise in serum creatinine due to their effects on the renin-angiotensin-aldosterone system.

To avoid prematurely discontinuing mortality-reducing therapies.

Determine the safety thresholds for continuing therapy.

A creatinine increase of up to

30\%

from baseline and a serum potassium of up to

5.5 \text{ mEq/L}

are considered acceptable parameters for continued therapy.

This patient's creatinine increased by roughly

16\%

and potassium is well below the

5.5 \text{ mEq/L}

threshold, indicating the regimen can be safely continued.

Key Concept

Expected physiological responses to renin-angiotensin-aldosterone system (RAAS) inhibitors in heart failure management

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic